For those that were unable to attend on Optimum’s 14th Annual Healthcare Investor Conference, or indeed would like a recap of what was shared on the day, we have been releasing the top takeaways from the panels! Our first panel of the day, chaired by Stephen Hansen, from BioCentury, saw a panel of blue chip […]
Dan Mahony and Gareth Powell are long time, successful life sciences and healthcare investors. They are luminaries of the UK and European healthcare ecosystem, who have been investing since the late 1990s and initially worked together at Polar Capital where together they set up the biotech and healthcare investment funds. Gareth is still Head of […]
Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]
Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3 STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022 20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is […]
